Design and Molecular Docking Studies of Quinazoline Derivatives as Antiproliferation
Downloads
Background: Nowadays, a lot of new active substances as anticancer agents have been developed. One of the protein targets of anticancer is selective cyclooxygenase-2 (COX-2). Selective COX-2 is the regulator of cell proliferation. Objective: In this research, quinazoline derivatives were used to design the anticancer agent through a selective COX-2 inhibition. The potential activity of quinazoline derivatives could be increased by substitution in position 2 and 3 of quinazolinone. Molecular docking of selective COX-2 inhibition was required to predict their antiproliferation activity. Methods: The molecular docking of quinazoline derivatives was carried out using Molegro Virtual Docker (MVD) Ver.5.5. Twenty-one of quinazoline derivatives were docked into selective COX-2 with PDB code 3LN1. The interaction was evaluated based on the re-ranked score comparison between quinazoline derivatives with co-crystallized ligand CEL_682. Celecoxib was used as the reference to this research. Results: The result indicated that 18 of 21 quinazoline derivatives showed the approximately re-ranked score -131.508 to -108.418 kcal/mol. Eight of these 18 new quinazoline derivatives have re-ranked score better than Celecoxib. Conclusions: In conclusion, 8 of the new quinazoline derivatives are feasible to be synthesize and performed their in vitro evaluation.
Bowman, A. L., Carlson H. A., Nikolovska-Coleska, Z., Zhong H. & Wang, S. (2007). Small molecule inhibitors of the MDM2–p53 interaction discovered by ensemblebased receptor models. J. Am. Chem. Soc.; 129; 12809-12814.
Cheng, L. S., Amaro, R. E., Xu, D., Li, W. W., Arzberger, P. W. & McCammon, J. A. (2008). Ensemble-based virtual screening reveals potential novelantiviral compounds for avian influenza neuraminidase. J. Med. Chem.; 51; 3878-3894.
Elangovan, M., Jayaraj, R. l., Ranjani, V. & Manigandan, K. (2013). Insilico Docking Studies To Identify Potent Inhibitors Of Alpha-Synuclein Aggregation In Parkinson Disease. Asian J Pharm Clin Res; 6(4); 127-131.
El-Azab, A. S., Al-Omar, M. A., Abdel-Aziz, A. A. M., Abdel-Aziz, N. I., El-Sayed, M. A. A., Aleisa, A. M., Sayed-Ahmed, M. M. & Abdel-Hamide, S. G. (2010). Design, synthesis and biological evaluation of novel quinazoline derivatives as potential antitumor agents: Molecular docking study. Eur. J. Med. Chem.; 45; 4188-4198.
IARC. (2012). GLOBOCAN 2012: Estimated cancer incidence, mortality, and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. Accessed at 16th April 2016
Noolvi, M. N. & Patel, H. M. (2011). Synthesis and in vitro antitumor activity of substituted quinazoline and quinoxaline derivatives: Search for anticancer agent. Eur. J. Med. Chem.; 46; 2327 – 2346.
Noolvi, M. N. & Patel H. M. (2013). Synthesis, method optimization, anticancer activity of 2,3,7-trisubstitued Quinazoline derivatives and targeting EGFR-tyrosine kinase by rational approach. Arabian Journal of Chemistry; 6; 35-48.
Sobolewski, C., Cerella, C., Dicato, M., Ghibelli, L. & Diederich, M. (2010). The Role of Cyclooxygenase-2 in Cell Proliferation and Cell Death Human Malignancies. Intr. J. Cell Bio; 1-21.
Zayed, M. F., Hany, E. A., Saleh, I., Abdell-Sattar, M., Omar & Adel, S. A. (2015). Synthesis and screening of some new fluorinated quinazolinone-esulphonamide hybrids as anticancer agents. Journal of Taibah University Medical Sciences;10(3); 333-339.
1. The copyright of this journal belongs to the Editorial Board and Journal Manager with the author's knowledge, while the moral right of the publication belong to the author.
2. The formal legal aspect of journal publication accessibility refers to the Creative Commons Attribution-Non-Commercial-Share Alike (CC BY-NC-SA), which implies that the publication can be used for non-commercial purposes in its original form.
3. Every publication (print/electronic) is open access for educational, research, and library purposes. In addition to the objectives mentioned above, the editorial board is not responsible for copyright infringement
.jpg)
